SEOUL (Reuters) – Samsung C&T Corp, de facto holding company of Samsung Group, is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in sub-subsidiary Samsung Bioepis Co Ltd, a South Korean TV channel reported on Monday.

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *